| Literature DB >> 25788903 |
Mogens Fenger1, Allan Linneberg2, Jørgen Jeppesen3.
Abstract
Common diseases like essential hypertension or diabetes mellitus are complex as they are polygenic in nature, such that each genetic variation only has a small influence on the disease. Genes operates in integrated networks providing the blue-print for all biological processes and conditional of the complex genotype determines the state and dynamics of any trait, which may be modified to various extent by non-genetic factors. Thus, diseases are heterogenous ensembles of conditions with a common endpoint. Numerous studies have been performed to define genes of importance for a trait or disease, but only a few genes with small effect have been identified. The major reasons for this modest progress is the unresolved heterogeneity of the regulation of blood pressure and the shortcomings of the prevailing monogenic approach to capture genetic effects in a polygenic condition. Here, a two-step procedure is presented in which physiological heterogeneity is disentangled and genetic effects are analyzed by variance decomposition of genetic interactions and by an information theoretical approach including 162 single nucleotide polymorphisms (SNP) in 84 genes in the sphingolipid metabolism and related networks in blood pressure regulation. As expected, almost no genetic main effects were detected. In contrast, two-gene interactions established the entire sphingolipid metabolic and related genetic network to be highly involved in the regulation of blood pressure. The pattern of interaction clearly revealed that epistasis does not necessarily reflects the topology of the metabolic pathways i.e., the flow of metabolites. Rather, the enzymes and proteins are integrated in complex cellular substructures where communication flows between the components of the networks, which may be composite in structure. The heritabilities for diastolic and systolic blood pressure were estimated to be 0.63 and 0.01, which may in fact be the maximum heritabilities of these traits. This procedure provide a platform for studying and capturing the genetic networks of any polygenic trait, condition, or disease.Entities:
Keywords: epistasis; genetic networks; heritability; hypertension; mutual information; phosphatidate metabolism; redox metabolism; sphingolipids
Year: 2015 PMID: 25788903 PMCID: PMC4349157 DOI: 10.3389/fgene.2015.00084
Source DB: PubMed Journal: Front Genet ISSN: 1664-8021 Impact factor: 4.599
Figure 1The sphingolipid metabolic network. The core biochemical network of the sphingolipid metabolism and the relation to the phosphatidate (LPA) and redox (Radical) networks. The canonical de novo pathway is initiated by a condensation of serine and palmitate by serine palmitoyltransferase (1). The product 3-keto-sphinganine is further processed to sphinganine by 3-ketodihydrosphingosine reductase (2), which can either by phosphorylated by sphingosine kinase (12) or converted to dihydroceramide by dihydroceramide synthase (3) and finally emerging as ceramide by the action of dihydroceramide desaturase (4). The faith of ceramide is then determined by the balance and interaction of several enzymes including ceramidase (8), sphingosine kinase (12), sphingomyelin synthase (5), sphingomyelinase (9), UDP-galactosyl ceramide glycosyltransferase (7)-galactosidase (11),UDP-glucose ceramide glycosyltransferase (6), and-glucosidase (10). Ceramide may also be phosphorylated to ceramide-1 phosphate by ceramide kinase (14), which may be reverted by a putative ceramide phosphatase (15). Sphingosine-1 phosphate may be dephosphorylated by sphingosine-1 phosphate phosphatase (13) or irreversibly degraded by sphingosine-1-phosphate lyase. Many of these enzymes has two or several isoforms. For a review see e.g., Lahiri and Futerman (2007). The salvage pathway (Lysosome) refers to the re-generation of sphingosine by acidic sphingomyelinase, galactosidase, and glucosidase that generates ceramides, which is further decomposed to sphingosine by acidic ceramidase. Please refer to Table S1a for abbreviation of the enzymes. For further information of the phosphatidate and redox metabolism related to the sphingolipid metabolism (see e.g., Ghelli et al., 2002; Won and Singh, 2006).
Figure 2The structural equation model (SEM). A simplified cartoon of the principal behind structural equation modeling (SEM). Here a cell is influenced by several “environmental” factors e.g., insulin (Ins) which induce a response in the cellular regulatory network cascade. The effect of this signal transduction is to induce or inhibit transcription of genes or genetic regulatory structures (Genomics). In addition, the signaling may directly influence the functionality of effector networks e.g., by promoting phosphorylation of effector proteins in all resulting in regulation of the blood pressure. In real life the pathway from the external factors to the ultimate response is much more complex as several cell types are involved in the local process (the vessel) and several tissues or organs will be involved (e.g., fatty acids generated in the liver) in a complex interactive network. The entire system is formulated by a complex set of matrix formulated regression algorithms, which may be proximal to the processes we actually can obtain information above or just by summary expressions. The subpopulations are then defined by simultaneous optimizing the SEM and the latent class (or rather latent profile) defining the population structure. A detailed account can be found in Muthen and Muthen (2004); Fenger (2008, 2012); Fenger et al. (2011).
Summary of significant interactions of WMI in diastolic blood pressure.
| 2 | 44 | 140 | 8197 | 244 | 34 |
| 3 | 143 | 68 | 1734 | 3 | 9 |
| 4 | 16 | 121 | 5058 | 318 | 16 |
| 5 | 53 | 125 | 6360 | 281 | 39 |
| 6 | 82 | 137 | 7411 | 224 | 43 |
| 7 | 85 | 135 | 6774 | 264 | 34 |
| 8 | 12 | 110 | 516 | 173 | 4 |
| 9 | 83 | 130 | 6483 | 265 | 40 |
| 10 | 23 | 124 | 6987 | 318 | 18 |
| 11 | 90 | 126 | 5724 | 257 | 41 |
| 12 | 14 | 113 | 5914 | 470 | 14 |
| 13 | 61 | 123 | 5915 | 288 | 43 |
| 14 | 16 | 117 | 3818 | 414 | 9 |
| 722 | 70,891 | 3521 | 344 | ||
| Fraction of possible epistasis | 42.60% | ||||
| WMI/epistasis ratio | 0.49% | ||||
| Unique WMI-significant interactions | 185 | 53.78% | |||
| Males | 1258 | 100 | 2911 | 8.70 | 16 |
| Females | 1251 | 69 | 1539 | 2.28 | 6 |
| 2509 | 4450 | 10.97 | 22 | ||
| WMI/epistasis ratio | 0.49% | ||||
Summary of significant interactions of WMI in systolic blood pressure.
| 2 | 44 | 140 | 8195 | 405 | 32 |
| 3 | 143 | 68 | 1752 | 5 | 11 |
| 4 | 16 | 121 | 1057 | 428 | 13 |
| 5 | 53 | 125 | 6374 | 405 | 38 |
| 6 | 82 | 137 | 7413 | 356 | 39 |
| 7 | 85 | 135 | 6752 | 490 | 36 |
| 8 | 12 | 110 | 255 | 0 | 0 |
| 9 | 83 | 130 | 6530 | 389 | 37 |
| 10 | 23 | 124 | 6984 | 546 | 18 |
| 11 | 90 | 126 | 5686 | 403 | 32 |
| 12 | 14 | 113 | 5136 | 773 | 14 |
| 13 | 61 | 123 | 5927 | 485 | 40 |
| 14 | 16 | 117 | 3586 | 661 | 9 |
| 722 | 65,647 | 5345 | 319 | ||
| Fraction of possible epistasis | 39.45% | ||||
| WMI/epistasis ratio | 0.49% | ||||
| Unique WMI-significant interactions | 182 | 57.05% | |||
| Males | 1258 | 100 | 2958 | 11.67 | 8 |
| Females | 1251 | 69 | 1548 | 2.97 | 3 |
| 2509 | 4506 | 14.64 | 11 | ||
| WMI/epistasis ratio | 0.24% | ||||
Prevalence of affected for two-SNP genotypes.
| rs865832 | SGPL1 | TT | rs12770335 | SGPL1 | GG | 0.0138 | 50 | 1.62 |
| rs309087 | LPPR5 | CC | rs5186 | AGTR1 | CC | 0.0279 | 50 | 1.3 |
| rs3734462 | AGPAT4 | TT | rs1799983 | NOS3 | TT | 0.0279 | 50 | 1.3 |
| rs1799883 | FABP2 | AA | rs1799983 | NOS3 | TT | 0.0220 | 45.45 | 1.62 |
| rs28385609 | SMPDL3A | TT | rs2003149 | KDSR | 0.0182 | 36.36 | 2.6 | |
| rs309087 | LPPR5 | CC | rs5186 | AGTR1 | CA | 0.0401 | 34.78 | 2.6 |
| rs243887 | SPTLC3 | TT | rs1071645 | ASAH1 | 0.0123 | 26.97 | 7.79 | |
| rs243887 | SPTLC3 | TT | rs1049874 | ASAH1 | GA | 0.0130 | 26.67 | 7.79 |
| rs41292584 | SMPDL3A | rs1799983 | NOS3 | GG | 0.0308 | 25 | 7.47 | |
| rs41292584 | SMPDL3A | rs3739709 | LPAR1 | CC | 0.0313 | 23.53 | 10.39 | |
| rs1138439 | PPAP2C | TT | rs12195587 | ELOVL2 | 0.0451 | 23.39 | 9.42 | |
| rs1138439 | PPAP2C | TT | rs2003149 | KDSR | 0.0377 | 23.13 | 11.04 | |
| rs3811514 | SPHKAP | GG | rs3828161 | SPHKAP | AA | 0.0371 | 22.17 | 14.61 |
| rs1799983 | NOS3 | rs2566514 | NOS3 | CC | 0.0008 | 10.18 | 16.23 | |
| rs3739968 | ASAH2B | GG | rs1071645 | ASAH1 | GG | 0.0341 | 10.16 | 6.17 |
| rs285 | LPL | TT | rs320 | LPL | GT | 0.0224 | 10.14 | 7.14 |
| rs3739968 | ASAH2B | GG | rs1049874 | ASAH1 | AA | 0.0314 | 9.94 | 5.84 |
| rs1799983 | NOS3 | rs3828161 | SPHKAP | 0.0123 | 9.87 | 7.47 | ||
| rs1130233 | AKT1 | rs3828161 | SPHKAP | 0.0215 | 9.84 | 6.17 | ||
| rs6109692 | SPTLC3 | rs2241883 | FABP1 | 0.0430 | 9.79 | 4.55 | ||
| rs11657217 | ENPP7 | GG | rs3734462 | AGPAT4 | 0.0479 | 6.67 | 1.3 | |
| rs6511701 | S1PR5 | rs1695 | GSTP1 | GG | 0.0358 | 6.15 | 1.3 | |
| rs11657217 | ENPP7 | GG | rs3170633 | GCLM | GG | 0.0010 | 4.35 | 1.3 |
| rs4880 | SOD2 | TT | rs11657217 | ENPP7 | GG | 0.0253 | 4.17 | 0.65 |
| rs5186 | AGTR1 | CC | rs67319648 | PPAPDC1A | 0.0485 | 3.23 | 0.32 | |
| rs398607 | GALC | CC | rs36211083 | CERK | TT | 0.0130 | 100 | 0.67 |
| rs398607 | GALC | TT | rs1805078 | GALC | 0.0124 | 80 | 0.89 | |
| rs1130233 | AKT1 | AA | rs3828161 | SPHKAP | GG | 0.0302 | 66.67 | 0.89 |
| rs243887 | SPTLC3 | TT | rs2241883 | FABP1 | GG | 0.0206 | 50 | 2.01 |
| rs1799983 | NOS3 | rs3828161 | SPHKAP | GG | 0.0236 | 42.86 | 2.68 | |
| rs1130435 | FABP6 | CC | rs7157599 | DEGS2 | GG | 0.0296 | 38.64 | 3.8 |
| rs7850023 | MIR4668 | rs5186 | AGTR1 | CC | 0.0400 | 36.73 | 4.03 | |
| rs5186 | AGTR1 | AA | rs2301022 | GCLM | AA | 0.0169 | 33.63 | 8.5 |
| rs1476387 | SMPD2 | TT | rs3739709 | LPAR1 | 0.0312 | 33.33 | 7.61 | |
| rs3739968 | ASAH2B | rs4918 | AHSG | GG | 0.0178 | 33.07 | 9.4 | |
| rs285 | LPL | CC | rs1695 | GSTP1 | AA | 0.0136 | 31.43 | 14.77 |
| rs12195587 | ELOVL2 | rs1476387 | SMPD2 | GG | 0.0183 | 30.84 | 14.77 | |
| rs1138439 | PPAP2C | TT | rs7302981 | CERS5 | CC | 0.0408 | 30.77 | 10.74 |
| rs6511701 | S1PR5 | rs1695 | GSTP1 | AA | 0.0123 | 30.63 | 18.57 | |
| rs285 | LPL | CC | rs7157599 | DEGS2 | AA | 0.0321 | 29.8 | 16.33 |
| rs12195587 | ELOVL2 | rs8176328 | SPHK1 | AG | 0.0182 | 29.77 | 20.58 | |
| rs12195587 | ELOVL2 | rs2247856 | SPHK1 | TC | 0.0195 | 29.65 | 21.03 | |
| rs12195587 | ELOVL2 | rs698912 | COL4A3BP | AA | 0.0407 | 28.42 | 23.71 | |
| rs6511701 | S1PR5 | GG | rs1868158 | SMPD3 | 0.0492 | 19.35 | 23.94 | |
| rs12195587 | ELOVL2 | CC | rs2247856 | SPHK1 | TC | 0.0338 | 19.21 | 26.17 |
| rs11657217 | ENPP7 | CC | rs402348 | KDSR | CA | 0.0359 | 17.34 | 9.62 |
| rs285 | LPL | TT | rs328 | LPL | CC | 0.0183 | 17.32 | 11.86 |
| rs1799983 | NOS3 | GG | rs3828161 | SPHKAP | 0.0119 | 16.33 | 8.95 | |
| rs3811515 | SPHKAP | rs16824283 | SPHKAP | 0.0137 | 16.32 | 8.72 | ||
| rs1138439 | PPAP2C | CC | rs36211083 | CERK | 0.0488 | 15.18 | 3.8 | |
| rs398607 | GALC | TT | rs36211083 | CERK | 0.0191 | 13.13 | 2.91 | |
| rs1049874 | ASAH1 | AA | rs4808863 | CERS1 | TT | 0.0237 | 12.16 | 2.01 |
| rs1071645 | ASAH1 | GG | rs4808863 | CERS1 | TT | 0.0237 | 12.16 | 2.01 |
| rs243887 | SPTLC3 | TT | rs1049874 | ASAH1 | AA | 0.0268 | 9.8 | 1.12 |
| rs243887 | SPTLC3 | TT | rs1071645 | ASAH1 | GG | 0.0192 | 9.43 | 1.12 |
| rs320 | LPL | GG | rs328 | LPL | CC | 0.0282 | 9.09 | 0.89 |
| rs79875317 | SMPD4 | AA | rs1695 | GSTP1 | GG | 0.002/0.001 | 71.43/54.17 | 1.62/2.91 |
| rs76033185 | SMPD4 | GG | rs1695 | GSTP1 | GG | 0.008/0.003 | 66.67/83.33 | 1.30/1.12 |
| rs1138439 | PPAP2C | TT | rs36211083 | CERK | TT | 0.044/0.038 | 44.44/55.56 | 1.30/1.12 |
| rs2297568 | SPTLC1 | AG | rs3828161 | SPHKAP | GG | 0.010/0.001 | 37.50/54.17 | 2.92/2.91 |
| rs12888666 | GALC | AA | rs1695 | GSTP1 | AA | 0.049/0.013 | 25.00/35.71 | 6.82/6.71 |
| rs1130233 | AKT1 | AA | rs243887 | SPTLC3 | TT | 0.014/0.015 | 50.00/60.00 | 1.62/134 |
| rs11657217 | ENPP7 | rs402348 | KDSR | CA | 0.016/0.043 | 22.27/29.3 | 18.51/16.78 | |
| rs3734462 | AGPAT4 | rs1049874 | ASAH1 | AA | 0.020/0.043 | 9.73/16.76 | 5.84/6.94 | |
| rs11657217 | ENPP7 | GG | rs402348 | KDSR | CA | 0.013/0.043 | 4.76/29.30 | 0.97/16.78 |
Prevalence of diastolic hypertension in the population 16.13% (threshold).
Number of subjects with diastolic hypertension captured by the significant genotypes 253 (82.14% of all affected).
Prevalence of systolic hypertension in the population 23.40% (threshold).
Number of subjects with systolic hypertension captured by the significant genotypes 436 (97.54% of all affected).
Genotypes in bold, missense mutations; genotypes in italic, synonymous mutations.
For gene abreviations, please see Supplemental Data Table S1a.
Freqencies of the affected by the two-SNP genotype (Genotype) and frequencies of the two-SNP genotype in the population (Population).
Figure 3Association between relative epistasis and WMI. The plots shows the heritability (Geno/Pheno) of the diastolic blood pressure as a function of the weighted mutual information (the plots of systolic blood pressure are similar). Subpopulation 8 was evaluated at an allocation threshold of 0.7 in contrast to 0.9 for all the other subpopulation (see Text for discussion). The three fitted plots [polynomial, Boltzmann (sigmoid), and Gaussian] were almost overlapping. Apart from the ubiquitous ASAH1 and SPHK1 haplotypes there is a difference in the ranking of the next interactions between the subpopulations. Similar differences in patterns were seen for the other subopulations.